GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan · Delayed Price · Currency is TWD 17.35
-0.20 (-1.14%)
Aug 26, 2026, 1:30 PM CST
GeneReach Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 238.08 | 232.74 | 206.49 | 225.46 | 750.02 | 1,012 | |
Revenue Growth | 6.10% | 12.71% | -8.42% | -69.94% | -25.89% | 18.09% |
Cost of Revenue | 64.78 | 71.82 | 88.21 | 197.88 | 259.95 | 265.1 |
Gross Profit | 173.3 | 160.93 | 118.28 | 27.58 | 490.07 | 746.98 |
Selling, General & Admin | 170.97 | 175.09 | 173.63 | 173.98 | 191.05 | 202.96 |
Research & Development | 61.69 | 72.75 | 80.51 | 61.46 | 58.81 | 56.61 |
Operating Expenses | 226.68 | 240.79 | 249.49 | 256.87 | 248.73 | 264.63 |
Operating Income | -53.38 | -79.86 | -131.22 | -229.29 | 241.34 | 482.35 |
Interest Expense | -5.25 | -6.51 | -5.93 | -5.76 | -6.61 | -6.26 |
Interest & Investment Income | 5.13 | 9.03 | 18 | 14.47 | 2.29 | 0.39 |
Currency Exchange Gain (Loss) | -21.52 | -21.52 | 28.89 | 0.45 | 29.39 | -11.55 |
Other Non Operating Income (Expenses) | 38.47 | -4.33 | 1.45 | 3.57 | 2.98 | 3.32 |
EBT Excluding Unusual Items | -36.55 | -103.19 | -88.81 | -216.55 | 269.38 | 468.24 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.04 |
Gain (Loss) on Sale of Assets | -0.5 | -0.5 | -0.57 | -1.39 | 1.7 | 0.41 |
Asset Writedown | -13 | -13 | -27.6 | - | - | - |
Other Unusual Items | 0.22 | 0.22 | - | -0.41 | 1.29 | 0.68 |
Pretax Income | -49.82 | -116.47 | -116.98 | -218.35 | 272.37 | 469.37 |
Income Tax Expense | -3.97 | -3.54 | 6.7 | -47.99 | 54.88 | 98.9 |
Earnings From Continuing Operations | -45.85 | -112.93 | -123.68 | -170.35 | 217.49 | 370.47 |
Minority Interest in Earnings | 2.76 | 2.65 | 4.95 | 4.08 | 3.85 | 6.15 |
Net Income | -43.09 | -110.28 | -118.73 | -166.27 | 221.34 | 376.62 |
Net Income to Common | -43.09 | -110.28 | -118.73 | -166.27 | 221.34 | 376.62 |
Net Income Growth | - | - | - | - | -41.23% | 46.38% |
Shares Outstanding (Basic) | 57 | 57 | 57 | 57 | 57 | 57 |
Shares Outstanding (Diluted) | 57 | 57 | 57 | 57 | 59 | 59 |
Shares Change | -0.48% | -0.79% | - | -3.08% | 1.13% | 1.88% |
EPS (Basic) | -0.75 | -1.93 | -2.07 | -2.89 | 3.85 | 6.55 |
EPS (Diluted) | -0.75 | -1.93 | -2.07 | -2.89 | 3.77 | 6.45 |
EPS Growth | - | - | - | - | -41.59% | 44.19% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.26 | -19.87 | -30.35 | -62.21 | 307.76 | 329.43 |
Free Cash Flow Per Share | 0.02 | -0.35 | -0.53 | -1.08 | 5.19 | 5.62 |
Dividend Per Share | - | - | - | - | 1.200 | 3.636 |
Dividend Growth | - | - | - | - | -67.00% | 45.43% |
Gross Margin | 72.79% | 69.14% | 57.28% | 12.23% | 65.34% | 73.81% |
Operating Margin | -22.42% | -34.31% | -63.55% | -101.70% | 32.18% | 47.66% |
Profit Margin | -18.10% | -47.38% | -57.50% | -73.75% | 29.51% | 37.21% |
Free Cash Flow Margin | 0.53% | -8.54% | -14.70% | -27.59% | 41.03% | 32.55% |
EBITDA | -6.15 | -22.24 | -69.95 | -174.3 | 292.82 | 531.28 |
EBITDA Margin | -2.58% | -9.55% | -33.88% | -77.31% | 39.04% | 52.49% |
D&A For EBITDA | 47.23 | 57.62 | 61.26 | 54.98 | 51.47 | 48.93 |
EBIT | -53.38 | -79.86 | -131.22 | -229.29 | 241.34 | 482.35 |
EBIT Margin | -22.42% | -34.31% | -63.55% | -101.70% | 32.18% | 47.66% |
Effective Tax Rate | - | - | - | - | 20.15% | 21.07% |
Revenue as Reported | - | - | - | 225.46 | 750.02 | 1,012 |